Holen Sie sich die Stockscreener-App
43.84
0.74%
0.305
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$43.54
Offen:
$43.43
24-Stunden-Volumen:
12.63M
Relative Volume:
0.94
Marktkapitalisierung:
$89.30B
Einnahmen:
$47.70B
Nettoeinkommen (Verlust:
$5.07B
KGV:
17.69
EPS:
2.4784
Netto-Cashflow:
$14.58B
1W Leistung:
-1.79%
1M Leistung:
-5.06%
6M Leistung:
-14.56%
1J Leistung:
-16.72%
1-Tages-Spanne:
$43.27
$43.90
1-Wochen-Bereich:
$43.27
$45.19
52-Wochen-Spanne:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
43.88 | 88.62B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
812.40 | 734.56B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.74 | 459.75B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
229.08 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.38 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.01 | 214.06B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Kardigan raises $254M to test cardio drugs from Sanofi, BMS and Ionis - Endpoints News
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Yahoo Finance
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
Bristol Myers Faces Legacy Headwinds But Banks On Its Pipeline - Finimize
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.
Bispecifics in Oncology Market Statistics Expected to Experience Major Growth by 2040, According to DelveInsight | AstraZeneca, I-MAB Biopharm, BioNTech, Bristol Myers Squibb - Barchart.com
Trend analysis for Bristol Myers Squibb Company this weekJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - BioSpace
Mark Cuban’s Pharmacy Targets Drug Pricing Reform as AstraZeneca Invests $4.5 Billion in Virginia and Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion - geneonline.com
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (NYSE:BMY) - Seeking Alpha
Bristol Myers (BMY) Triggers Milestone Payment with SystImmune C - GuruFocus
SystImmune receives $250 million milestone payment from Bristol Myers Squibb - Investing.com
Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition - ICLG.com
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus - Seeking Alpha
Bristol-Myers Squibb (BMY): Exploring Valuation After Recent Share Price Declines - simplywall.st
Bristol Myers Squibb: Value Emerges From Distress - Seeking Alpha
Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status - Yahoo Finance
Conning Inc. Has $33.17 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Fourpath Capital Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CAR Ts for autoimmune ramp up: BMS buying Orbital for $1.5B - BioWorld MedTech
BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology
Bristol Myers to buy Cambridge startup Orbital Therapeutics, building out cell therapy pipeline - The Boston Globe
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push | Business Information & News | FE - Westlaw Today
What's Going On With Bristol Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition - GuruFocus
Chart based analysis of Bristol Myers Squibb Company trendsEntry Point & Fast Moving Market Watchlists - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
BMS latest to enter in vivo CAR-T field with $1.5B Orbital buy - FirstWord Pharma
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push - Reuters
Bristol Myers Squibb To Acquire Orbital Therapeutics - citybiz
Bristol Myers makes $1.5B bid for Orbital Therapeutics - The Pharma Letter
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push By Reuters - Investing.com
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Bill - GuruFocus
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acq - GuruFocus
Bristol Myers Squibb to acquire Orbital for $1.5B - NJBIZ
Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion - Investing.com
$1.5B deal: Bristol Myers Squibb acquires Orbital, gaining OTX-201 and RNA in vivo CAR T platform - Stock Titan
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection – Company AnnouncementFT.com - Financial Times
Blair William & Co. IL Sells 222,590 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Sold by Vontobel Holding Ltd. - MarketBeat
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
Abel Hall LLC Has $444,000 Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shell Asset Management Co. Raises Position in Bristol Myers Squibb Company $BMY - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):